OR WAIT null SECS
September 14, 2015.
The pneumonia vaccine market, estimated at US$5.9 bn in 2014, is expected to reach US$11 bn by 2020, according to a new report. The Global Pneumonia Vaccine Market Outlook 2020 states that the developing regions are expected join the USA and Europe in accounting for a "significant share" of the market, because of rising incidences of the disease and the regions' increasing purchasing power. Governments' focus on preventive healthcare strategies to cut down costs is also set to play a major role.
The introduction of the 10-valent pneumococcal conjugate vaccine, PCV10, decreases the rates of clinical pneumonia even in unvaccinated children. With a greater number of serotypes in current vaccines, there has been more disease reduction in both vaccinated and unvaccinated populations. As vaccines evolve, similar improvements can be expected, the report adds.